Exondys 51 Dosage: What Patients Need to Know

Here’s the short answer: the FDA‑approved dose of Exondys 51 (eteplirsen) is **30 mg per kilogram of body weight, given once a week as a 35‑ to 60‑minute IV infusion**. Below we’ll walk through how that dose is calculated, why it matters, what you can expect in terms of safety, and how the cost stacks up against other exon‑skipping therapies like Vyondys 53. Let’s get straight to the point—no fluff, just what you need to know.

Quick Answer – Dosage

Exact Prescribed Dose

The label says 30 mg/kg once weekly. That’s it—no loading dose, no “start low and go slow” titration. The amount is fixed based on the patient’s weight, and the infusion must be administered over 35–60 minutes.

How to Calculate the Dose

Patient Weight	Required Dose (mg)	Example Vial Combination
40 kg (≈88 lb)	1 200 mg	2 × 500 mg vials + 1 × 100 mg vial
70 kg (≈154 lb)	2 100 mg	4 × 500 mg vials – 1 × 100 mg vial
100 kg (≈220 lb)	3 000 mg	6 × 500 mg vials

Because the drug comes in 100 mg and 500 mg vials, clinicians usually round to the nearest 100 mg to match vial strengths. Always double‑check the calculation with the pharmacy before the infusion.

How Exondys Works

Mechanism of Action

Exondys 51 contains eteplirsen, an antisense oligonucleotide that binds to exon 51 of the dystrophin gene. By “skipping” that exon during mRNA processing, the drug enables the body to produce a shortened but partially functional dystrophin protein. Think of it as a clever editing trick that lets the muscle cells read the genetic script just well enough to make a functional—if not perfect—protein.

Why the 30 mg/kg Dose Matters

Clinical trials showed that the 30 mg/kg weekly regimen produced a measurable increase in dystrophin levels compared with lower‑dose arms. The study, published in *Molecular Therapy*, found an average 0.9%‑increase in dystrophin after 48 weeks, and those gains correlated with modest improvements in the six‑minute walk test. In short, the approved dose strikes the balance between efficacy and safety.

Exondys 51 vs. Vyondys 53

Both drugs share the same dosing strategy—30 mg/kg once weekly—but they target different exons. Vyondys 53 (golodirsen) skips exon 53, making it an option for a separate subset of Duchenne muscular dystrophy (DMD) patients. The similarity in dosing means the infusion logistics are alike, yet the clinical outcomes differ because they address distinct genetic mutations.

FDA Approval Details

Approval History

Exondys 51 received accelerated approval from the U.S. Food and Drug Administration in September 2016 under the FDA label. The agency granted approval based on surrogate endpoints—specifically, the increase in dystrophin protein—because there was an unmet medical need for DMD patients amenable to exon 51 skipping.

Key Label Statements

• “Do not exceed 30 mg/kg once weekly.”
• Infuse over 35–60 minutes using a 0.2‑micron inline filter.
• Monitor liver enzymes (AST/ALT) and renal function before and during therapy.

Where to Find the Official Prescribing Information

All the details you’ll ever need are in the FDA‑approved prescribing information, which you can download from the FDA website. That PDF is the gold standard if you want to verify dosage limits, contraindications, or infusion practices.

Safety & Side Effects

Common Adverse Reactions

The most frequently reported side effects include:

• Headache
• Fever
• Nausea
• Infusion‑site reactions (redness, swelling)
• Elevated liver enzymes

These events are usually mild and manageable with pre‑medication or a brief pause in the infusion.

Monitoring Recommendations

Before each infusion, clinicians check vital signs and perform a quick visual inspection of the IV site. Blood work is drawn at baseline, then every three months to keep an eye on liver function and kidney health. If labs spike, the infusion may be delayed until the values normalize.

Managing an Infusion Reaction

Should an allergic‑type reaction arise—hives, wheezing, or a sudden drop in blood pressure—the infusion must be stopped immediately. The nurse will administer antihistamines or epinephrine as needed, then reassess. Most patients can resume therapy after the episode resolves, often with a small pre‑medication adjustment.

Real‑World Experience

One family shared that their 12‑year‑old son experienced a mild fever after his third infusion. A quick dose of acetaminophen and an extra 10‑minute observation period solved the issue, and the weekly schedule continued without further hiccups. Stories like this illustrate that, while side effects exist, they’re generally predictable and treatable.

Cost & Insurance

What’s the Price Tag?

According to recent market data, the wholesale acquisition cost (WAC) for Exondys 51 ranges from **$300,000 to $350,000 per year** for a 30‑kg patient. This figure reflects the high cost of manufacturing antisense oligonucleotides and the limited patient pool.

Comparison with Vyondys 53 and Other Therapies

Drug	Approx. Annual Cost	Approved Indication
Exondys 51	$300‑350 K	DMD amenable to exon 51 skipping
Vyondys 53	$400‑420 K	DMD amenable to exon 53 skipping

Insurance Navigation Tips

Getting coverage can feel like a maze, but a solid prior‑authorization packet makes all the difference. Include:

• A physician’s letter stating the genetic test result (exon 51 amenable)
• Relevant excerpts from the FDA label
• Documentation of the patient’s functional status
• Any prior‑treatment history

Sarepta’s “Patient Support Services” program offers financial assistance for eligible families. It’s worth calling their helpline early in the process to explore co‑pay relief or charitable grants.

Practical Administration

Step‑by‑Step Infusion Prep

1. Confirm the patient’s weight on the day of infusion.
2. Calculate the exact dose (30 mg/kg) using the table above.
3. Dilute the required vials in sterile 0.9% saline to a final volume of ≤ 250 mL.
4. Insert a 0.2‑micron inline filter into the line (as mandated by the FDA label).
5. Program the infusion pump for a 35–60‑minute run.
6. Monitor the patient’s vitals before, during, and after the infusion.

Infusion‑Site Best Practices

Rotate peripheral IV sites every few weeks to avoid irritation. If you notice any redness or swelling, alert the nurse right away—early detection prevents larger complications.

What to Keep Nearby

During the infusion, it helps to have a few comfort items on hand: a water bottle, a favorite book or tablet, and the phone number of your clinic’s nurse line. Some families even bring a calming playlist to keep the atmosphere relaxed.

FAQs You Might Be Wondering About

Can the dose be increased above 30 mg/kg? No—exceeding the label dose is not allowed and could raise safety concerns.

Is a loading dose required? No, therapy begins directly at the weekly 30 mg/kg dose.

Can Exondys 51 be given at home? Yes, provided a qualified infusion nurse follows the label guidelines.

What filters are required? A 0.2‑micron inline filter is mandatory for every infusion.

How long does each infusion last? Between 35 and 60 minutes, depending on pump settings and patient tolerance.

Conclusion

Understanding the exondys 51 dosage—30 mg per kilogram, once a week—is the first step toward a safe and effective treatment journey for DMD patients. By mastering the calculation, respecting the FDA label, staying alert to side effects, and tackling the cost conversation head‑on, you empower yourself or a loved one to make informed decisions. If you’re navigating insurance hurdles, reach out to Sarepta’s patient‑support team early; if you have concerns about side effects, keep an open line with your neurologist. Knowledge is power, and together we can turn those numbers on a page into real‑world hope.